End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
56,600 KRW | -1.91% | -4.87% | -21.39% |
May. 03 | SK Bioscience's Attributable Loss Narrows in Q1 | MT |
Mar. 28 | SK Bioscience Signs Deal with Sanofi for Five Vaccine Types | MT |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Vaccine/Biopharmaceuticals
100.0
%
| 456,726 | 100.0 % | 369,506 | 100.0 % | -19.10% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
America
50.3
%
| 217,834 | 47.7 % | 185,961 | 50.3 % | -14.63% |
South Korea
42.8
%
| 224,157 | 49.1 % | 158,217 | 42.8 % | -29.42% |
Europe
5.7
%
| 13,778 | 3.0 % | 21,202 | 5.7 % | +53.88% |
Asia
1.1
%
| 651 | 0.1 % | 3,893 | 1.1 % | +497.76% |
Middle East
0.1
%
| 305 | 0.1 % | 232 | 0.1 % | -24.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jae-Yong An
CEO | Chief Executive Officer | 56 | - |
Yong-Sung Choi
DFI | Director of Finance/CFO | 51 | - |
Sally Choe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jong-Gu Park
CTO | Chief Tech/Sci/R&D Officer | 59 | - |
Hun Kim
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Young-Joo Park
IRC | Investor Relations Contact | 54 | - |
Harry Kleanthous
PRN | Corporate Officer/Principal | - | 22-10-20 |
Ji-Hyun Yoo
LAW | General Counsel | 46 | - |
Su-Ahn Yoo
SAM | Sales & Marketing | 51 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Choi
BRD | Director/Board Member | 60 | - |
Chang-Jin Moon
BRD | Director/Board Member | 71 | - |
Jae-Yong An
CEO | Chief Executive Officer | 56 | - |
Mi-Jin Cho
BRD | Director/Board Member | 62 | - |
Gwang-Hyun Jeon
BRD | Director/Board Member | 59 | - |
Hun Kim
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Ik-Hwan Kwon
BRD | Director/Board Member | 57 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 76,827,750 | 24,186,505 ( 31.48 %) | 0 | 31.48 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
NOVAVAX, INC. 4.64% | 6,500,000 | 4.64% | 25,675,000 $ |
Company contact information
SK bioscience Co., Ltd.
310 Pangyo-ro Bundang-gu
13494, Seongnam-si
+82 2 2008 2200
http://www.skbioscience.co.krSector
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.39% | 3.19B | |
-2.23% | 90.02B | |
-1.18% | 39.15B | |
-15.83% | 31.71B | |
+62.86% | 26.47B | |
-21.68% | 14.34B | |
-8.73% | 12.89B | |
-15.05% | 11.18B | |
-45.69% | 10.97B | |
+4.94% | 8.94B |
- Stock Market
- Equities
- A302440 Stock
- Company SK bioscience Co.,Ltd.